20May 2016 by Ronny Allan No Comments

Translate

Ronny Allan

Award winning Neuroendocrine Cancer Patient Advocate. Diagnosed with Metastatic Neuroendocrine Cancer in 2010.

Update 2021: Trial complete. Results:

The first results of this trial were presented at ASCO 2020 where it was concluded as follows:

“This initial planned analysis demonstrates similarly high 15-month PFS for CAPTEM/PRRT relative to PRRT alone. OTRR (objective tumour response rate (complete or partial response)) is numerically higher but at the cost of greater toxicity. Longer follow-up is required to determine if the activity of PRRT/CAPTEM is sufficient to warrant Phase III evaluation” – click here to read the abstract.

Combination treatments are common in chemotherapy, but this trial was different as it effectively combined the use of different therapies both with their own toxicity risks, albeit low in each therapy type. The use of PRRT and chemo (in particular CAPTEM) or ‘PRCRT’. The attached video is a presentation by Dr Michael Hofman who I see regularly on twitter posting some very interesting stuff. He’s a great advocate for NET patients. The video will explain in some detail how the treatment is thought to work together.

‘CONTROLNETS’ involving PRRT and CAPTEM. The clinical trial document read here: CLICK HERE.

Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.

Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.